X | ||||||||||
- Definition Decrease in research and development expenses related to grants recognized. No definition available.
|
X | ||||||||||
- Definition Grants remaining to be awarded. No definition available.
|
X | ||||||||||
- Definition Highly Liquid Investments Maturity Period No definition available.
|
X | ||||||||||
- Definition Receivable from grants for costs incurred. No definition available.
|
X | ||||||||||
- Definition Summary of Significant Accounting Policies [Line Items] No definition available.
|
X | ||||||||||
- Definition Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Fair value of financial and nonfinancial obligations. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI). No definition available.
|
X | ||||||||||
- Definition The amount of customer funding recorded as an offset to costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|